1
|
Nimura Y, Madeda Y, Tamura E, Kouyama Y, Matsudaira S, Nakamura H, Misawa M, Miyachi H, Baba T, Mukai S, Sawada N, Ishida F, Nemoto T, Kudo SE. Gastrointestinal: Real-time observation of rectal malignant lymphoma using endocytoscopy for differentiation from adenocarcinoma. J Gastroenterol Hepatol 2023; 38:1456. [PMID: 36863707 DOI: 10.1111/jgh.16155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Revised: 02/14/2023] [Accepted: 02/19/2023] [Indexed: 03/04/2023]
Affiliation(s)
- Y Nimura
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
| | - Y Madeda
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
| | - E Tamura
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
| | - Y Kouyama
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
| | - S Matsudaira
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
| | - H Nakamura
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
| | - M Misawa
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
| | - H Miyachi
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
| | - T Baba
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
| | - S Mukai
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
| | - N Sawada
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
| | - F Ishida
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
| | - T Nemoto
- Department of Diagnostic Pathology, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
| | - S-E Kudo
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
| |
Collapse
|
2
|
Fukui H, Baba T, Kurogi Y. Erratum: "Calculation of nuclear spin-spin couplings. X. Analytical derivative method of perturbation energy" [J. Chem. Phys. 112, 3532 (2000)]. J Chem Phys 2021; 155:069902. [PMID: 34391345 DOI: 10.1063/5.0064810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- H Fukui
- Kitami Institute of Technology, 165 Koencho, Kitami 090-8507, Japan
| | - T Baba
- Kitami Institute of Technology, 165 Koencho, Kitami 090-8507, Japan
| | - Y Kurogi
- Kitami Institute of Technology, 165 Koencho, Kitami 090-8507, Japan
| |
Collapse
|
3
|
Baba T, Fujimori Y, Kurihara K, Yamanaka Y, Hashimoto S, Terasawa Y, Hata H, Yokota D, Wakabayashi T, Imai T. A bolus of saline injection leads to increase in coronary flow based on the viscosity reduction effect: the mechanism of saline induced Pd/Pa ratio. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
In conjunction with fractional flow reserve (FFR), our previous study has shown the accuracy and utility of saline induced Pd/Pa ratio (SPR) for the assessment of myocardial ischemia. However, the potential mechanism how saline injection leads to increase in coronary flow remains speculative.
Purpose
This study aimed to clarify the underlying mechanism of SPR by using swine models.
Methods
The study was conducted in four swine models, and bolus of 25°C saline, 40°C saline, and 25°C dextran was injected at rates of 40mL/5sec through a catheter inserted into the superior mesenteric artery. Its peripheral arterioles were observed and recorded by a digital microscope, and transit time of each fluid and a luminal diameter of arterioles before and after injection were measured.
Results
The result from arterioles diameters of pre- and post-injection (0.049±0.016mm vs. 0.050±0.016mm; P=0.636) indicated that luminal diameters remained unchanged regardless of fluid administration. The transit time of 25°C saline was significantly shorter than 25°C dextran (3.19±0.68sec vs. 6.15±1.19sec; P<0.0001). Although the result showed no significance, the transit time of 40°C saline with lower viscosity was shorten compared to 25°C saline (3.1±0.43sec vs. 3.65±0.46sec; P=0.088).
Conclusions
Compared to 25°C dextran (viscosity of 4.991mPa·s) having the same viscosity as 37°C whole blood, 25°C saline (viscosity of 1.012mPa·s) caused increasing to double the intravascular flow volume without dilating arterioles. The results strongly suggested that the potential mechanism of SPR was viscosity reduction effect. Combined with FFR which is based on vasodilation-mediated hyperemia, these findings may contribute to clarifying the pathophysiology and especially the microcirculation in coronary artery diseases.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- T Baba
- Rikuzankai Iida Hospital, Iida, Japan
| | | | | | | | | | | | - H Hata
- Suwa Central Hospital, Chino, Japan
| | - D Yokota
- Rikuzankai Iida Hospital, Iida, Japan
| | | | - T Imai
- Suwa Central Hospital, Chino, Japan
| |
Collapse
|
4
|
Yamanaka Y, Fujimori Y, Hashimoto S, Kurihara K, Wakabayashi T, Imai T, Baba T, Takeuchi W, Yokota D. The developing mechanism of atherosclerotic lesion in coronary side branch on the ventricular free wall differs by the location of lesion. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The effective treating method of coronary side branch lesions such as ostial stenosis or thin arteries has not been established. On the other hand, tortuous side branch rarely has stenotic lesions.
Purpose
We focused on coronary side branches on the ventricular free wall, and examined coronary risk factors and bending and stretching motion of branch which can contribute to the development of atherosclerotic lesion.
Methods
In elective and first-time coronary angiograms, we included side branches on the ventricular free wall (>2mm in diameter) and excluded previously treated ones. Study A; we divided arteries into proximal, middle, and distal segment, and examined the presence of tortuosity and stenotic lesions exceeding 50% diameter stenosis (DS) for each segment. A score of 1 was assigned to tortuous segment, and 0 to non-tortuous one. Study B; we included stenotic lesion (>50% DS) in side branch ostium and excluded those extended across main coronary arteries. Relation between lesions and patients' characteristics was examined.
Results
Study A; in 1,828 side branches from 472 patients, middle and distal segments had significantly higher tortuosity score than proximal (0.68, 0.78 vs. 0.34; p<0.0001). On the contrary, proximal segments had more stenotic lesions except ostial stenosis (230 vs. 69, 5; p<0.0001). Study B; in 1,740 side branches from 465 patients, 122 ostial stenotic lesions were found (7.0%). Multivariate logistic regression analysis revealed diabetes mellitus and age as independent contributors to development of ostial stenosis (Table).
Conclusions
Side branch stenosis developed less frequently in middle and distal segments, where stronger ventricular wall motion reinforces bending and stretching motion and tortuosity of arteries. This fact indicates that those characteristics may prevent developing atherosclerosis through increasing shear stress. On the other hand, diabetes mellitus strongly contributes to the development of ostial stenosis. Thus, the developing mechanism of atherosclerotic lesion in side branch on the ventricular free wall differs by the location of lesion.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
| | | | | | | | | | - T Imai
- Suwa Central Hospital, Chino, Japan
| | - T Baba
- Iida Hospital, Cardiology, Iida, Japan
| | | | - D Yokota
- Iida Hospital, Cardiology, Iida, Japan
| |
Collapse
|
5
|
Liu Y, Ye YL, Lou JL, Yang XF, Baba T, Kimura M, Yang B, Li ZH, Li QT, Xu JY, Ge YC, Hua H, Wang JS, Yang YY, Ma P, Bai Z, Hu Q, Liu W, Ma K, Tao LC, Jiang Y, Hu LY, Zang HL, Feng J, Wu HY, Han JX, Bai SW, Li G, Yu HZ, Huang SW, Chen ZQ, Sun XH, Li JJ, Tan ZW, Gao ZH, Duan FF, Tan JH, Sun SQ, Song YS. Positive-Parity Linear-Chain Molecular Band in ^{16}C. Phys Rev Lett 2020; 124:192501. [PMID: 32469564 DOI: 10.1103/physrevlett.124.192501] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 03/31/2020] [Accepted: 04/22/2020] [Indexed: 06/11/2023]
Abstract
An inelastic excitation and cluster-decay experiment ^{2}H(^{16}C,^{4}He+^{12}Be or ^{6}He+^{10}Be)^{2}H was carried out to investigate the linear-chain clustering structure in neutron-rich ^{16}C. For the first time, decay paths from the ^{16}C resonances to various states of the final nuclei were determined, thanks to the well-resolved Q-value spectra obtained from the threefold coincident measurement. The close-threshold resonance at 16.5 MeV is assigned as the J^{π}=0^{+} band head of the predicted positive-parity linear-chain molecular band with (3/2_{π}^{-})^{2}(1/2_{σ}^{-})^{2} configuration, according to the associated angular correlation and decay analysis. Other members of this band were found at 17.3, 19.4, and 21.6 MeV based on their selective decay properties, being consistent with the theoretical predictions. Another intriguing high-lying state was observed at 27.2 MeV which decays almost exclusively to ^{6}He+^{10}Be(∼6 MeV) final channel, corresponding well to another predicted linear-chain structure with the pure σ-bond configuration.
Collapse
Affiliation(s)
- Y Liu
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - Y L Ye
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - J L Lou
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - X F Yang
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - T Baba
- Kitami Institute of Technology, 090-8507 Kitami, Japan
| | - M Kimura
- Department of Physics, Hokkaido University, 060-0810 Sapporo, Japan
| | - B Yang
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - Z H Li
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - Q T Li
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - J Y Xu
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - Y C Ge
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - H Hua
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - J S Wang
- School of Science, Huzhou University, Huzhou 313000, China
- Institute of Modern Physics, Chinese Academy of Science, Lanzhou 730000, China
| | - Y Y Yang
- Institute of Modern Physics, Chinese Academy of Science, Lanzhou 730000, China
| | - P Ma
- Institute of Modern Physics, Chinese Academy of Science, Lanzhou 730000, China
| | - Z Bai
- Institute of Modern Physics, Chinese Academy of Science, Lanzhou 730000, China
| | - Q Hu
- Institute of Modern Physics, Chinese Academy of Science, Lanzhou 730000, China
| | - W Liu
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - K Ma
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - L C Tao
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - Y Jiang
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - L Y Hu
- Fundamental Science on Nuclear Safety and Simulation Technology Laboratory, Harbin Engineering University, Harbin 150001, China
| | - H L Zang
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - J Feng
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - H Y Wu
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - J X Han
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - S W Bai
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - G Li
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - H Z Yu
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - S W Huang
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - Z Q Chen
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - X H Sun
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - J J Li
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - Z W Tan
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - Z H Gao
- Institute of Modern Physics, Chinese Academy of Science, Lanzhou 730000, China
| | - F F Duan
- Institute of Modern Physics, Chinese Academy of Science, Lanzhou 730000, China
| | - J H Tan
- Fundamental Science on Nuclear Safety and Simulation Technology Laboratory, Harbin Engineering University, Harbin 150001, China
| | - S Q Sun
- Fundamental Science on Nuclear Safety and Simulation Technology Laboratory, Harbin Engineering University, Harbin 150001, China
| | - Y S Song
- Fundamental Science on Nuclear Safety and Simulation Technology Laboratory, Harbin Engineering University, Harbin 150001, China
| |
Collapse
|
6
|
Hinterleitner B, Knapp I, Poneder M, Shi Y, Müller H, Eguchi G, Eisenmenger-Sittner C, Stöger-Pollach M, Kakefuda Y, Kawamoto N, Guo Q, Baba T, Mori T, Ullah S, Chen XQ, Bauer E. Thermoelectric performance of a metastable thin-film Heusler alloy. Nature 2019; 576:85-90. [DOI: 10.1038/s41586-019-1751-9] [Citation(s) in RCA: 151] [Impact Index Per Article: 30.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Accepted: 08/22/2019] [Indexed: 11/09/2022]
|
7
|
Sasaki S, Oikado K, Saito Y, Tominaga J, Sata M, Sakai F, Kato T, Iwasawa T, Kenmotsu H, Kusumoto M, Baba T, Endo M, Fujiwara Y, Sugiura H, Yanagawa N, Ito Y, Sakamoto T, Ohe Y, Kuwano K. Radiographic characteristics and poor prognostic factors of interstitial lung disease (ILD) in nivolumab-treated patients with non-small cell lung cancer (NSCLC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
So M, Miyamoto T, Murakami R, Kawahara S, Abiko K, Yamaguchi K, Horie A, Hamanishi J, Kondoh E, Baba T, Mandai M. The efficacy of secondary debulking surgery for recurrent ovarian, tubal and peritoneal cancer in low risk scores in the Tian model. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.04.597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Abiko K, Horikawa N, Murakami R, Yamaguchi K, Hamanishi J, Baba T, Mandai M. GM-CSF increases myeloid-derived suppressor cells infiltration after anti-VEGF therapy in ovarian cancer. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.04.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Ezura M, Kikuchi A, Ishiki A, Okamura N, Hasegawa T, Harada R, Watanuki S, Funaki Y, Hiraoka K, Baba T, Sugeno N, Oshima R, Yoshida S, Kobayashi J, Kobayashi M, Tano O, Nakashima I, Mugikura S, Iwata R, Taki Y, Furukawa K, Arai H, Furumoto S, Tashiro M, Yanai K, Kudo Y, Takeda A, Aoki M. Longitudinal changes in 18 F-THK5351 positron emission tomography in corticobasal syndrome. Eur J Neurol 2019; 26:1205-1211. [PMID: 30980575 DOI: 10.1111/ene.13966] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Accepted: 04/04/2019] [Indexed: 12/01/2022]
Abstract
BACKGROUND AND PURPOSE Corticobasal syndrome (CBS) is pathologically characterized by tau deposits in neuronal and glial cells and by reactive astrogliosis. In several neurodegenerative disorders, 18 F-THK5351 has been observed to bind to reactive astrocytes expressing monoamine oxidase B. In this study, the aim was to investigate the progression of disease-related pathology in the brains of patients with CBS using positron emission tomography with 18 F-THK5351. METHODS Baseline and 1-year follow-up imaging were acquired using magnetic resonance imaging and positron emission tomography with 18 F-THK5351 in 10 subjects: five patients with CBS and five age-matched normal controls (NCs). RESULTS The 1-year follow-up scan images revealed that 18 F-THK5351 retention had significantly increased in the superior parietal gyrus of the patients with CBS compared with the NCs. The median increases in 18 F-THK5351 accumulation in the patients with CBS were 6.53% in the superior parietal gyrus, 4.34% in the precentral gyrus and 4.33% in the postcentral gyrus. In contrast, there was no significant increase in the regional 18 F-THK5351 retention in the NCs. CONCLUSIONS Longitudinal increases in 18 F-THK5351 binding can be detected over a short interval in the cortical sites of patients with CBS. A monoamine oxidase B binding radiotracer could be useful in monitoring the progression of astrogliosis in CBS.
Collapse
Affiliation(s)
- M Ezura
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - A Kikuchi
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - A Ishiki
- Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - N Okamura
- Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.,Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - T Hasegawa
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - R Harada
- Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - S Watanuki
- Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
| | - Y Funaki
- Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
| | - K Hiraoka
- Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
| | - T Baba
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - N Sugeno
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - R Oshima
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - S Yoshida
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - J Kobayashi
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - M Kobayashi
- Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan
| | - O Tano
- Department of Neurology, Sendai Medical Center, Sendai, Japan
| | - I Nakashima
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.,Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan
| | - S Mugikura
- Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - R Iwata
- Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
| | - Y Taki
- Department of Nuclear Medicine and Radiology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - K Furukawa
- Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.,Division of Community of Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan
| | - H Arai
- Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - S Furumoto
- Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
| | - M Tashiro
- Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
| | - K Yanai
- Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Y Kudo
- Division of Neuroimaging, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - A Takeda
- Department of Neurology, National Hospital Organization, Sendai Nishitaga Hospital, Sendai, Japan
| | - M Aoki
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| |
Collapse
|
11
|
Powell CA, Camidge DR, Gemma A, Kusumoto M, Baba T, Kuwano K, Bankier A, Kiura K, Tamura K, Modi S, Tsurutani J, Doi T, Iwata H, Krop IE, Zhang L, Jasmeet S, Saito K, Shahidi J, Yver A, Takahashi S. Abstract P6-17-06: Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: Analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payload. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-17-06] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Several classes of anti-cancer agents including certain immunotherapies, systemic chemotherapies, and targeted therapies including trastuzumab and T-DM1 increase the risk of interstitial lung disease (ILD) and fatal cases have been reported. For DS-8201a, interim efficacy and safety analyses of available data established a final recommended dose of 5.4 mg/kg IV q3wk in advanced HER2-positive breast cancer (BC). Based on preliminary clinical results, ILD was identified as an important risk for DS-8201a. A robust monitoring and management plan was established across all studies and an international, independent ILD adjudication committee (AC) reviews the cases reported as ILD on an ongoing basis.
Methods: All subjects (sbj) who received ≥1 dose of DS-8201a across 7 ongoing studies were included in this analysis. Reported ILD (standardized MedDRA Query terms) included the terms ILD, pneumonitis, and organizing pneumonia. ILD frequencies were calculated based on investigator's assessment and after adjudication. The analysis of potential risk factors associated with ILD is ongoing.
Results: As of 21 June 2018, 448 sbj received ≥1 dose of DS-8201a across multiple tumor types, including BC. Of the 321 sbj with BC, 173 (53.9%) were from Japan, 103 (32.1%) from the US, and 45 (14.0%) from 6 other countries (Spain, South Korea, Taiwan, Belgium, France, and Italy). These sbj received 1 of 7 doses of DS-8201a (0.8 mg/kg: 3 sbjs, 1.6 mg/kg: 1 sbj, 3.2 mg/kg: 3 sbjs, 5.4 mg/kg: 111 sbjs, 6.4 mg/kg: 178 sbj, 7.4 mg/kg: 20 sbj, 8.0 mg/kg: 5 sbj). Overall, 44 cases of potential ILD were reported by the investigators across all tumor types (44/448, 9.8%; Grade ≥3 10/448, 2.2%). In sbj with BC who received 5.4 mg/kg, any grade and Grade ≥3 investigator-reported ILD were 7.2% (8/111) and 0.9% (1/111), respectively. The ILD AC assessed 30 of 44 cases; 22 were considered drug-related ILD, 4 were ILD but not drug-related, and 4 were found not to be ILD. For adjudicated drug-related ILD cases, the median time to onset was 159 (range; 46-591) days from the time of first dose.
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 All Grades All tumors, All doses (N=448) Investigator-reported20 (4.5)14 (3.1)4 (0.9)1 (0.2)5 (1.1)44 (9.8)Cases adjudicated13840530Adjudicated as drug-related ILD9 (2.0)6 (1.3)3 (0.7)04 (0.9)22 (4.9) BC, All doses (N=321) Investigator-reported17 (5.3)11 (3.4)3 (0.9)1 (0.3)4 (1.2)36 (11.2)Cases adjudicated11830426Adjudicated as drug-related ILD8 (2.5)6 (1.9)3 (0.9)04 (1.2)21 (6.5) BC, 5.4 mg/kg (N=111) Investigator-reported4 (3.6)3 (2.7)001 (0.9)8 (7.2)Cases adjudicated120014Adjudicated as drug-related ILD00001 (0.9)1 (0.9)n (%), except where noted
Conclusions: These analyses confirm that ILD is an important identified risk for DS-8201a. Further analyses are ongoing to better understand the potential risk factors associated with the incidence of on-treatment ILD. When ILD is suspected, early diagnosis through appropriate imaging, laboratory tests, and pulmonary consultation as well as prompt management with steroids are recommended.
Citation Format: Powell CA, Camidge DR, Gemma A, Kusumoto M, Baba T, Kuwano K, Bankier A, Kiura K, Tamura K, Modi S, Tsurutani J, Doi T, Iwata H, Krop IE, Zhang L, Jasmeet S, Saito K, Shahidi J, Yver A, Takahashi S. Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: Analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payload [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-06.
Collapse
Affiliation(s)
- CA Powell
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - DR Camidge
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - A Gemma
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - M Kusumoto
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Baba
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - K Kuwano
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - A Bankier
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - K Kiura
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - K Tamura
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - S Modi
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - J Tsurutani
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Doi
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - H Iwata
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - IE Krop
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - L Zhang
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - S Jasmeet
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - K Saito
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - J Shahidi
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - A Yver
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - S Takahashi
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| |
Collapse
|
12
|
Baba T, Ting AY, Tkachenko O, Xu J, Stouffer RL. Direct actions of androgen, estrogen and anti-Müllerian hormone on primate secondary follicle development in the absence of FSH in vitro. Hum Reprod 2018; 32:2456-2464. [PMID: 29077845 DOI: 10.1093/humrep/dex322] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2017] [Accepted: 10/03/2017] [Indexed: 11/14/2022] Open
Abstract
STUDY QUESTION What are effects of androgen, estrogen and anti-Müllerian hormone (AMH), independent of FSH action, on the development and function of primate follicles from the preantral to small antral stage in vitro? SUMMARY ANSWER Androgen and estrogen, but not AMH, promote follicle survival and growth in vitro, in the absence of FSH. However, their growth-promoting effects are limited to the preantral to early antral stage. WHAT IS KNOWN ALREADY FSH supports primate preantral follicle development in vitro. Androgen and estrogen augment follicle survival and growth in the presence of FSH during culture. STUDY DESIGN SIZE, DURATION Nonhuman primate model; randomized, control versus treatment groups. Rhesus macaque (n = 6) secondary follicles (n = 24 per animal per treatment group) were cultured for 5 weeks. PARTICIPANTS/MATERIALS, SETTING, METHODS Follicles were encapsulated in 0.25% (w/v) alginate and cultured individually in modified alpha minimum essential media with (i) FSH (1 ng/ml; control), (ii) no FSH, (iii) no FSH + estradiol (E2; 100 pg/ml)/dihydrotestosterone (DHT; 50 ng/ml) and (iv) no FSH + AMH (50 ng/ml). In a second experiment, follicles were cultured with (i) FSH (1 ng/ml), (ii) no FSH, (iii) no FSH + E2 (1 ng/ml), (iv) no FSH + DHT (50 ng/ml) and (v) no FSH + E2/DHT. Follicle survival, antrum formation and growth pattern were evaluated. Progesterone (P4), E2 and AMH concentrations in culture media were measured. MAIN RESULTS AND THE ROLE OF CHANCE In the first experiment, FSH deprivation significantly decreased (P < 0.05) follicle survival rates in the no FSH group (16 ± 5%), compared to CTRL (66 ± 9%). E2/DHT (49 ± 5%), but not AMH (27 ± 8%), restored follicle survival rate to the CTRL level. Similarly, antrum formation rates were higher (P < 0.05) in CTRL (56 ± 6%) and E2/DHT groups (54 ± 14%), compared to no FSH (0 ± 0%) and AMH (11 ± 11%) groups. However, follicle growth rate after antrum formation and follicle diameter at week 5 was reduced (P < 0.05) in the E2/DHT group (405 ± 25 μm), compared to CTRL (522 ± 29 μm). Indeed, the proportion of fast-grow follicles at week 5 was higher in CTRL (29% ± 5), compared to E2/DHT group (10 ± 3%). No fast-grow follicles were observed in no FSH and AMH groups. AMH levels at week 3 remained similar in all groups. However, media concentrations of P4 and E2 at week 5 were lower (P < 0.05, undetectable) in no FSH, E2/DHT and AMH groups, compared to CTRL (P4 = 93 ± 10 ng/ml; E2 = 4 ± 1 ng/ml). In the second experiment, FSH depletion diminished follicle survival rate (66 ± 8% in control versus 45 ± 9% in no FSH, P = 0.034). E2 plus DHT (31.5 ± 11%) or DHT alone (69 ± 9%) restored follicle survival rate to the control (FSH) level as expected. Also, E2 plus DHT or DHT alone improved antrum formation rate. However, in the absence of FSH, E2 plus DHT or DHT alone did not support growth, in terms of follicle diameter, or steroid (P4 or E2) production after the antral stage. LIMITATIONS REASONS FOR CAUTION This study is limited to in vitro effects of E2, DHT and AMH during the interval from the secondary to small antral stage of macaque follicular development. In addition, the primate follicle pool is heterogeneous and differs between animals; therefore, even though only secondary follicles were selected, follicle growth and developmental outcomes might differ from one animal to another. WIDER IMPLICATIONS OF THE FINDINGS This study provides novel information on the possible actions of estrogen and androgen during early follicular development in primates. Our results suggest that sequential exposure of preantral follicles to local factors, e.g. E2 and DHT, followed by gonadotropin once the follicle reaches the antral stage, may better mimic primate folliculogenesis in vivo. STUDY FUNDING/COMPETING INTEREST(S) Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Center for Translational Research on Reproduction and Infertility 5P50HD071836, and the NIH Primate Centers Program 8P510D011092. There are no conflicts of interest.
Collapse
Affiliation(s)
- T Baba
- Division of Reproductive and Developmental Sciences, Oregon National Primate Research Center, 505 NW 185th Avenue, Beaverton, OR 97006, USA
- Department of Obstetrics and Gynecology, Sapporo Medical University, South 1 West 16, Sapporo, Hokkaido 060-8543 Japan
| | - A Y Ting
- Division of Reproductive and Developmental Sciences, Oregon National Primate Research Center, 505 NW 185th Avenue, Beaverton, OR 97006, USA
| | - O Tkachenko
- Division of Reproductive and Developmental Sciences, Oregon National Primate Research Center, 505 NW 185th Avenue, Beaverton, OR 97006, USA
| | - J Xu
- Division of Reproductive and Developmental Sciences, Oregon National Primate Research Center, 505 NW 185th Avenue, Beaverton, OR 97006, USA
- Department of Obstetrics and Gynecology, School of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
| | - R L Stouffer
- Division of Reproductive and Developmental Sciences, Oregon National Primate Research Center, 505 NW 185th Avenue, Beaverton, OR 97006, USA
- Department of Obstetrics and Gynecology, School of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
| |
Collapse
|
13
|
Usui Y, Kenmotsu H, Mori K, Ono A, Yoh K, Baba T, Fujiwara Y, Yamaguchi O, Ko R, Okamoto H, Yamamoto N, Ninomiya T, Ogura T, Kato T. A multicenter single-arm phase II study of nab-paclitaxel/carboplatin for non-small cell lung cancer patients with interstitial lung disease. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.060] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Hashimoto S, Fujimori Y, Baba T, Kurihara K, Ebisuda K, Terasawa Y, Wakabayashi T, Yamazaki K, Imai T. P3658Saline induced Pd/Pa ratio can predict functional significance of coronary stenosis assessed using fractional flow reserve. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | - Y Fujimori
- Suwa Central Hospital, Chino, Nagano, Japan
| | - T Baba
- Suwa Central Hospital, Chino, Nagano, Japan
| | - K Kurihara
- Suwa Central Hospital, Chino, Nagano, Japan
| | - K Ebisuda
- Suwa Central Hospital, Chino, Nagano, Japan
| | - Y Terasawa
- Suwa Central Hospital, Chino, Nagano, Japan
| | | | - K Yamazaki
- Showa Inan General Hospital, Komagane, Nagano, Japan
| | - T Imai
- Suwa Central Hospital, Chino, Nagano, Japan
| |
Collapse
|
15
|
Hayashi T, Ueda S, Mori M, Baba T, Abe T, Iwata H. Influence of resveratrol pretreatment on thawed bovine embryo quality and mitochondrial DNA copy number. Theriogenology 2018; 106:271-278. [DOI: 10.1016/j.theriogenology.2017.10.022] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Revised: 10/09/2017] [Accepted: 10/15/2017] [Indexed: 01/23/2023]
|
16
|
Baba T, Kawasaki I, Mori E, Takeda A. Mechanisms underlying loss of awareness of hyposmia in Parkinson's disease. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
17
|
OSHITARI T, Bikbova G, Baba T, Yamamoto S. Regenerative therapies with combined axoprotectants in AGE
-exposed retinas. Acta Ophthalmol 2017. [DOI: 10.1111/j.1755-3768.2017.0f072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- T. OSHITARI
- Ophthalmology and Visual Science; Chiba University Graduate School of Medicine; Chiba Japan
| | - G. Bikbova
- Ophthalmology and Visual Science; Chiba University Graduate School of Medicine; Chiba Japan
| | - T. Baba
- Ophthalmology and Visual Science; Chiba University Graduate School of Medicine; Chiba Japan
| | - S. Yamamoto
- Ophthalmology and Visual Science; Chiba University Graduate School of Medicine; Chiba Japan
| |
Collapse
|
18
|
Murakami H, Ohe Y, Hida T, Sakai H, Kasahara K, Imamura F, Baba T, Kubota K, Hosomi Y, Shimokawa T, Hayashi H, Miyadera K, Tamura T, Nishio M. Phase I study of TAS-121, a novel third-generation epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Hashimoto S, Fujimori Y, Yamazaki K, Baba T, Nishiyama S, Yamanaka Y, Ebisuda K, Kurihara K, Wakabayashi T, Imai T. P2388Efficay of intracoronary saline injection induced Pd/Pa ratio to evaluate functional significance of coronary artery stenosis assessed by fractional flow reserve. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Hanai U, Akamatsu T, Kobayashi M, Tsunoda Y, Hirabayashi K, Baba T, Atsumi H, Matsumae M. A Case of Occipital Malignant Peripheral Nerve Sheath Tumor with Neurofibromatosis Type 1. Tokai J Exp Clin Med 2016; 41:130-134. [PMID: 27628604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Accepted: 06/15/2016] [Indexed: 06/06/2023]
Abstract
INTRODUCTION The prognosis of malignant peripheral nerve sheath tumor (MPNST) with neurofibromatosis type 1 (NF-1) is worse than that of a solitary MPNST, because of the tumor size and location difficult to resect completely. We experienced a case of MPNST in the occipital region with NF-1. CASE REPORT A 59-year-old woman presented with NF-1 and an MPNST of the occipital region. We performed wide excision involving the occipital bone, and reconstructed with a titanium plate and a free latissimus dorsi muscle flap. Despite three operations and postoperative radiotherapy, the tumor locally recurred after each surgery; further complicated by lung and mediastinal metastasis. Adjuvant therapy was insufficient to control local recurrence, which was observed intracranially, resulting in sagittal sinus invasion. Thirty months after the initial surgery, the patient died of respiratory failure due to lung metastasis. CONCLUSION MPNST with NF-1 has poorer prognosis than that of a solitary lesion. Recently, it is reported in several literature that combination therapy with surgery and radiotherapy improve survival rates. But as we presented, when the complete local resection with free margin could not achieved due to the size and anatomical location of the tumor, the effectiveness of radiotherapy is not sufficient to control local recurrence.
Collapse
Affiliation(s)
- Ushio Hanai
- Department of Plastic Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Baba T, Ting A, Tkachenko O, Xu J, Stouffer R. Androgen and estrogen promote macaque preantral follicle survival and growth in the absence of fsh during 3-dimensional culture. Fertil Steril 2016. [DOI: 10.1016/j.fertnstert.2016.07.151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
22
|
Murakami R, Baba Y, Furusawa M, Nishimura R, Nakaura T, Baba T, Katsura F, Eura M, Masuyama K, Takahashi M. Early glottic squamous cell carcinoma: Predictive value of MR imaging for the rate of 5-year local control with radiation therapy. Acta Radiol 2016. [DOI: 10.1258/rsmacta.41.1.38] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Purpose: To evaluate MR findings in early (T1 and T2 stages) glottic carcinomas and the predictive value of MR imaging for the rate of 5-year local control with radiation therapy. Material and Methods: Eighty-three patients with early glottic carcinomas were prospectively examined with MR at 1.5 T. MR investigation included unenhanced T1-weighted, T2-weighted, dynamic and contrast-enhanced T1-weighted images. Three patients with presumed advanced diseases on MR were initially treated with total laryngectomy and were excluded from the study. The remaining 80 patients were treated with radiation therapy with curative intent. Tumor detectability, size and relationship to the thyroid cartilage were determined on MR images. The MR findings were then correlated with the rate of local control. Results: Forty-eight of 80 lesions (60%) were detected on MR imaging. All detected lesions but 1 demonstrated increased signal on T2-weighted images. The lesions were best delineated on dynamic images (statistically significant). The 5-year local control rate with radiation therapy was 72%. Univariate analysis revealed clinical T stage, MR detectability, tumor size and relationship to the thyroid cartilage as significant predictors. Multivariate analysis revealed that the relationship to the thyroid cartilage was an independent factor. Conclusion: MR provides prognostic information about the results of definitive radiation therapy. To evaluate the tumor extension in lesions detected on precontrast MR images, contrast-enhanced dynamic images should be obtained.
Collapse
Affiliation(s)
- R. Murakami
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - Y. Baba
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - M. Furusawa
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - R. Nishimura
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - T. Nakaura
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - T. Baba
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - F. Katsura
- Department of Otorhinolaryngology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - M. Eura
- Department of Otorhinolaryngology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - K. Masuyama
- Department of Otorhinolaryngology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - M. Takahashi
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| |
Collapse
|
23
|
Narita W, Nishio Y, Baba T, Iizuka O, Ishihara T, Matsuda M, Iwasaki M, Tominaga T, Mori E. High-Convexity Tightness Predicts the Shunt Response in Idiopathic Normal Pressure Hydrocephalus. AJNR Am J Neuroradiol 2016; 37:1831-1837. [PMID: 27365329 DOI: 10.3174/ajnr.a4838] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2016] [Accepted: 04/18/2016] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Although neuroimaging plays an important role in the diagnosis of idiopathic normal pressure hydrocephalus, its predictive value for response to shunt surgery has not been established. The purpose of the current study was to identify neuroimaging markers that predict the shunt response of idiopathic normal pressure hydrocephalus. MATERIALS AND METHODS Sixty patients with idiopathic normal pressure hydrocephalus underwent presurgical brain MR imaging and clinical evaluation before and 1 year after shunt surgery. The assessed MR imaging features included the Evans index, high-convexity tightness, Sylvian fissure dilation, callosal angle, focal enlargement of the cortical sulci, bumps in the lateral ventricular roof, and deep white matter and periventricular hyperintensities. The idiopathic normal pressure hydrocephalus grading scale total score was used as a primary clinical outcome measure. We used measures for individual symptoms (ie, the idiopathic normal pressure hydrocephalus grading scale subdomain scores, such as gait, cognitive, and urinary scores), the Timed Up and Go test, and the Mini-Mental State Examination as secondary clinical outcome measures. The relationships between presurgical neuroimaging features and postoperative clinical changes were investigated by using simple linear regression analysis. To identify the set of presurgical MR imaging features that best predict surgical outcomes, we performed multiple linear regression analysis by using a bidirectional stepwise method. RESULTS Simple linear regression analyses demonstrated that presurgical high-convexity tightness, callosal angle, and Sylvian fissure dilation were significantly associated with the 1-year changes in the clinical symptoms. A multiple linear regression analysis demonstrated that presurgical high-convexity tightness alone predicted the improvement of the clinical symptoms 1 year after surgery. CONCLUSIONS High-convexity tightness is a neuroimaging feature predictive of shunt response in idiopathic normal pressure hydrocephalus.
Collapse
Affiliation(s)
- W Narita
- From the Departments of Behavioral Neurology and Cognitive Neuroscience (W.N., Y.N., T.B., O.I., T.I., M.M., E.M.)
| | - Y Nishio
- From the Departments of Behavioral Neurology and Cognitive Neuroscience (W.N., Y.N., T.B., O.I., T.I., M.M., E.M.)
| | - T Baba
- From the Departments of Behavioral Neurology and Cognitive Neuroscience (W.N., Y.N., T.B., O.I., T.I., M.M., E.M.)
| | - O Iizuka
- From the Departments of Behavioral Neurology and Cognitive Neuroscience (W.N., Y.N., T.B., O.I., T.I., M.M., E.M.)
| | - T Ishihara
- From the Departments of Behavioral Neurology and Cognitive Neuroscience (W.N., Y.N., T.B., O.I., T.I., M.M., E.M.)
| | - M Matsuda
- From the Departments of Behavioral Neurology and Cognitive Neuroscience (W.N., Y.N., T.B., O.I., T.I., M.M., E.M.)
| | - M Iwasaki
- Neurosurgery (M.I., T.T.), Tohoku University School of Medicine, Sendai, Japan
| | - T Tominaga
- Neurosurgery (M.I., T.T.), Tohoku University School of Medicine, Sendai, Japan
| | - E Mori
- From the Departments of Behavioral Neurology and Cognitive Neuroscience (W.N., Y.N., T.B., O.I., T.I., M.M., E.M.)
| |
Collapse
|
24
|
Matsuo K, Takazawa Y, Ross MS, Elishaev E, Podzielinski I, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Matsuzaki S, Baba T, Satoh S, Shida M, Nishikawa T, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Fujiwara K, Hazama Y, Kadogami D, Moffitt MN, Takeuchi S, Nishimura M, Iwasaki K, Ushioda N, Johnson MS, Yoshida M, Hakam A, Li SW, Richmond AM, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Yamaguchi K, Oishi T, Kajiwara H, Hasegawa K, Yasuda M, Kawana K, Suda K, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Wakatsuki A, Sugiyama T, Pejovic T, Nagano T, Shimoya K, Andoh M, Shiki Y, Enomoto T, Sasaki T, Fujiwara K, Mikami M, Shimada M, Konishi I, Kimura T, Post MD, Shahzad MM, Im DD, Yoshida H, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. Ann Oncol 2016; 27:1257-66. [PMID: 27052653 DOI: 10.1093/annonc/mdw161] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2015] [Accepted: 03/29/2016] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND To examine the effect of the histology of carcinoma and sarcoma components on survival outcome of uterine carcinosarcoma. PATIENTS AND METHODS A multicenter retrospective study was conducted to examine uterine carcinosarcoma cases that underwent primary surgical staging. Archived slides were examined and histologic patterns were grouped based on carcinoma (low-grade versus high-grade) and sarcoma (homologous versus heterologous) components, correlating to clinico-pathological demographics and outcomes. RESULTS Among 1192 cases identified, 906 cases were evaluated for histologic patterns (carcinoma/sarcoma) with high-grade/homologous (40.8%) being the most common type followed by high-grade/heterologous (30.9%), low-grade/homologous (18.0%), and low-grade/heterologous (10.3%). On multivariate analysis, high-grade/heterologous (5-year rate, 34.0%, P = 0.024) and high-grade/homologous (45.8%, P = 0.017) but not low-grade/heterologous (50.6%, P = 0.089) were independently associated with decreased progression-free survival (PFS) compared with low-grade/homologous (60.3%). In addition, older age, residual disease at surgery, large tumor, sarcoma dominance, deep myometrial invasion, lymphovascular space invasion, and advanced-stage disease were independently associated with decreased PFS (all, P < 0.01). Both postoperative chemotherapy (5-year rates, 48.6% versus 39.0%, P < 0.001) and radiotherapy (50.1% versus 44.1%, P = 0.007) were significantly associated with improved PFS in univariate analysis. However, on multivariate analysis, only postoperative chemotherapy remained an independent predictor for improved PFS [hazard ratio (HR) 0.34, 95% confidence interval (CI) 0.27-0.43, P < 0.001]. On univariate analysis, significant treatment benefits for PFS were seen with ifosfamide for low-grade carcinoma (82.0% versus 49.8%, P = 0.001), platinum for high-grade carcinoma (46.9% versus 32.4%, P = 0.034) and homologous sarcoma (53.1% versus 38.2%, P = 0.017), and anthracycline for heterologous sarcoma (66.2% versus 39.3%, P = 0.005). Conversely, platinum, taxane, and anthracycline for low-grade carcinoma, and anthracycline for homologous sarcoma had no effect on PFS compared with non-chemotherapy group (all, P > 0.05). On multivariate analysis, ifosfamide for low-grade/homologous (HR 0.21, 95% CI 0.07-0.63, P = 0.005), platinum for high-grade/homologous (HR 0.36, 95% CI 0.22-0.60, P < 0.001), and anthracycline for high-grade/heterologous (HR 0.30, 95% CI 0.14-0.62, P = 0.001) remained independent predictors for improved PFS. Analyses of 1096 metastatic sites showed that carcinoma components tended to spread lymphatically, while sarcoma components tended to spread loco-regionally (P < 0.001). CONCLUSION Characterization of histologic pattern provides valuable information in the management of uterine carcinosarcoma.
Collapse
Affiliation(s)
- K Matsuo
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, USA
| | - Y Takazawa
- Department of Pathology, Cancer Institute Hospital, Tokyo, Japan
| | - M S Ross
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology
| | - E Elishaev
- Department of Pathology, MaGee-Womens Hospital, University of Pittsburgh, Pittsburgh
| | - I Podzielinski
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky, Lexington, USA
| | - M Yunokawa
- Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - T B Sheridan
- Department of Pathology, Mercy Medical Center, Baltimore
| | - S H Bush
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of South Florida, Tampa
| | - M M Klobocista
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Bronx
| | - E A Blake
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology; University of Colorado, Boulder, USA
| | - T Takano
- Department of Obstetrics and Gynecology, Tohoku University, Miyagi
| | - S Matsuzaki
- Department of Obstetrics and Gynecology, Osaka University, Osaka
| | - T Baba
- Department of Obstetrics and Gynecology, Kyoto University, Kyoto
| | - S Satoh
- Department of Obstetrics and Gynecology, Tottori University, Tottori
| | - M Shida
- Department of Obstetrics and Gynecology, Tokai University, Kanagawa
| | - T Nishikawa
- Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama
| | - Y Ikeda
- Departments of Obstetrics and Gynecology, The University of Tokyo, Tokyo
| | - S Adachi
- Department of Obstetrics and Gynecology, Niigata University, Niigata
| | - T Yokoyama
- Department of Obstetrics and Gynecology, Osaka Rosai Hospital, Osaka
| | - M Takekuma
- Department of Obstetrics and Gynecology, Shizuoka Cancer Center, Shizuoka
| | - K Fujiwara
- Department of Obstetrics and Gynecology, Kurashiki Medical Center, Okayama
| | - Y Hazama
- Department of Obstetrics and Gynecology, Kawasaki Medical School, Okayama
| | - D Kadogami
- Department of Obstetrics and Gynecology; Kitano Hospital, Osaka, Japan
| | - M N Moffitt
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Portland, USA
| | - S Takeuchi
- Department of Obstetrics and Gynecology, Iwate Medical University, Morioka
| | - M Nishimura
- Department of Obstetrics and Gynecology, Tokushima University, Tokushima
| | - K Iwasaki
- Department of Obstetrics and Gynecology, Aichi Medical University, Aichi
| | - N Ushioda
- Department of Gynecology, Cancer Institute Hospital, Tokyo
| | - M S Johnson
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky, Lexington, USA
| | - M Yoshida
- Departments of Pathology, National Cancer Center Hospital, Tokyo, Japan
| | - A Hakam
- Department of Pathology, Moffitt Cancer Center, University of South Florida, Tampa
| | - S W Li
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Bronx
| | - A M Richmond
- Department of Pathology, University of Colorado, Boulder
| | - H Machida
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, USA
| | - P Mhawech-Fauceglia
- Department of Pathology, University of Southern California, Los Angeles, USA
| | - Y Ueda
- Department of Obstetrics and Gynecology, Osaka University, Osaka
| | - K Yoshino
- Department of Obstetrics and Gynecology, Osaka University, Osaka
| | - K Yamaguchi
- Department of Obstetrics and Gynecology, Kyoto University, Kyoto
| | - T Oishi
- Department of Obstetrics and Gynecology, Tottori University, Tottori
| | - H Kajiwara
- Department of Pathology, Tokai University, Kanagawa
| | - K Hasegawa
- Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama
| | - M Yasuda
- Department of Pathology, Saitama Medical University International Medical Center, Saitama
| | - K Kawana
- Departments of Obstetrics and Gynecology, The University of Tokyo, Tokyo
| | - K Suda
- Department of Obstetrics and Gynecology, Niigata University, Niigata
| | - T M Miyake
- Department of Obstetrics and Gynecology, Kawasaki Medical School, Okayama
| | - T Moriya
- Department of Pathology, Kawasaki Medical School, Okayama
| | - Y Yuba
- Department of Pathology, Kitano Hospital, Osaka, Japan
| | - T Morgan
- Department of Pathology, Oregon Health & Science University, Portland, USA
| | - T Fukagawa
- Department of Pathology, Iwate Medical University, Morioka
| | - A Wakatsuki
- Department of Obstetrics and Gynecology, Aichi Medical University, Aichi
| | - T Sugiyama
- Department of Obstetrics and Gynecology, Iwate Medical University, Morioka
| | - T Pejovic
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Portland, USA
| | - T Nagano
- Department of Obstetrics and Gynecology; Kitano Hospital, Osaka, Japan
| | - K Shimoya
- Department of Obstetrics and Gynecology, Kawasaki Medical School, Okayama
| | - M Andoh
- Department of Obstetrics and Gynecology, Kurashiki Medical Center, Okayama
| | - Y Shiki
- Department of Obstetrics and Gynecology, Osaka Rosai Hospital, Osaka
| | - T Enomoto
- Department of Obstetrics and Gynecology, Niigata University, Niigata
| | - T Sasaki
- Department of Pathology, The University of Tokyo, Tokyo, Japan
| | - K Fujiwara
- Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama
| | - M Mikami
- Department of Obstetrics and Gynecology, Tokai University, Kanagawa
| | - M Shimada
- Department of Obstetrics and Gynecology, Tottori University, Tottori
| | - I Konishi
- Department of Obstetrics and Gynecology, Kyoto University, Kyoto
| | - T Kimura
- Department of Obstetrics and Gynecology, Osaka University, Osaka
| | - M D Post
- Department of Pathology, University of Colorado, Boulder
| | - M M Shahzad
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of South Florida, Tampa
| | - D D Im
- Department of Gynecology, Mercy Medical Center, Baltimore
| | - H Yoshida
- Departments of Pathology, National Cancer Center Hospital, Tokyo, Japan
| | - K Omatsu
- Department of Gynecology, Cancer Institute Hospital, Tokyo
| | - F R Ueland
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky, Lexington, USA
| | - J L Kelley
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology
| | - R G Karabakhtsian
- Department of Pathology, University of Kentucky, Lexington Department of Pathology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, USA
| | - L D Roman
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, USA
| |
Collapse
|
25
|
Kisamori K, Shimoura S, Miya H, Michimasa S, Ota S, Assie M, Baba H, Baba T, Beaumel D, Dozono M, Fujii T, Fukuda N, Go S, Hammache F, Ideguchi E, Inabe N, Itoh M, Kameda D, Kawase S, Kawabata T, Kobayashi M, Kondo Y, Kubo T, Kubota Y, Kurata-Nishimura M, Lee CS, Maeda Y, Matsubara H, Miki K, Nishi T, Noji S, Sakaguchi S, Sakai H, Sasamoto Y, Sasano M, Sato H, Shimizu Y, Stolz A, Suzuki H, Takaki M, Takeda H, Takeuchi S, Tamii A, Tang L, Tokieda H, Tsumura M, Uesaka T, Yako K, Yanagisawa Y, Yokoyama R, Yoshida K. Candidate Resonant Tetraneutron State Populated by the ^{4}He(^{8}He,^{8}Be) Reaction. Phys Rev Lett 2016; 116:052501. [PMID: 26894705 DOI: 10.1103/physrevlett.116.052501] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Indexed: 06/05/2023]
Abstract
A candidate resonant tetraneutron state is found in the missing-mass spectrum obtained in the double-charge-exchange reaction ^{4}He(^{8}He,^{8}Be) at 186 MeV/u. The energy of the state is 0.83±0.65(stat)±1.25(syst) MeV above the threshold of four-neutron decay with a significance level of 4.9σ. Utilizing the large positive Q value of the (^{8}He,^{8}Be) reaction, an almost recoilless condition of the four-neutron system was achieved so as to obtain a weakly interacting four-neutron system efficiently.
Collapse
Affiliation(s)
- K Kisamori
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Shimoura
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - H Miya
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Michimasa
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - S Ota
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - M Assie
- IPN Orsay, 15 Rue, Georges, Clemenceau 91400 Orsay, France
| | - H Baba
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Baba
- Department of Physics, Kyoto University, Yoshida-Honcho, Sakyo, Kyoto 606-8501, Japan
| | - D Beaumel
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- IPN Orsay, 15 Rue, Georges, Clemenceau 91400 Orsay, France
| | - M Dozono
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Fujii
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - N Fukuda
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Go
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - F Hammache
- IPN Orsay, 15 Rue, Georges, Clemenceau 91400 Orsay, France
| | - E Ideguchi
- Research Center for Nuclear Physics, Osaka University, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| | - N Inabe
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M Itoh
- Cyclotron and Radioisotope Center, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi 980-8578, Japan
| | - D Kameda
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Kawase
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - T Kawabata
- Department of Physics, Kyoto University, Yoshida-Honcho, Sakyo, Kyoto 606-8501, Japan
| | - M Kobayashi
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - Y Kondo
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8550, Japan
| | - T Kubo
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Kubota
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | | | - C S Lee
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Maeda
- Faculty of Engineering, University of Miyazaki, 1-1 Gakuen, Kibanadai-nishi, Miyazaki 889-2192, Japan
| | - H Matsubara
- National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage, Chiba, Japan
| | - K Miki
- Research Center for Nuclear Physics, Osaka University, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| | - T Nishi
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - S Noji
- National Superconducting Cyclotron Laboratory, Michigan State University, 640 S Shaw Lane, East Lansing, Michigan 48824, USA
| | - S Sakaguchi
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Kyushu University, 6-10-1 Hakozaki, Higashi, Fukuoka 812-8581, Japan
| | - H Sakai
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Sasamoto
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - M Sasano
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Sato
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Shimizu
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - A Stolz
- National Superconducting Cyclotron Laboratory, Michigan State University, 640 S Shaw Lane, East Lansing, Michigan 48824, USA
| | - H Suzuki
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M Takaki
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - H Takeda
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Takeuchi
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - A Tamii
- Research Center for Nuclear Physics, Osaka University, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| | - L Tang
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - H Tokieda
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - M Tsumura
- Department of Physics, Kyoto University, Yoshida-Honcho, Sakyo, Kyoto 606-8501, Japan
| | - T Uesaka
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - K Yako
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - Y Yanagisawa
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - R Yokoyama
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - K Yoshida
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| |
Collapse
|
26
|
Yokouchi H, Baba T, Oshitari T, Yamamoto S. Correlation between peripapillary retinal thickness and serum level of vascular endothelial growth factor in patients with POEMS syndrome. Acta Ophthalmol 2015. [DOI: 10.1111/j.1755-3768.2015.0321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- H. Yokouchi
- Ophthalmology and Visual Science; Graduate School of Medicine; Chiba University; Chiba Japan
| | - T. Baba
- Ophthalmology and Visual Science; Graduate School of Medicine; Chiba University; Chiba Japan
| | - T. Oshitari
- Ophthalmology and Visual Science; Graduate School of Medicine; Chiba University; Chiba Japan
| | - S. Yamamoto
- Ophthalmology and Visual Science; Graduate School of Medicine; Chiba University; Chiba Japan
| |
Collapse
|
27
|
Baba T, Hagino H, Nonomiya H, Ikuta T, Shoda E, Mogami A, Sawaguchi T, Kaneko K. Inadequate management for secondary fracture prevention in patients with distal radius fracture by trauma surgeons. Osteoporos Int 2015; 26:1959-63. [PMID: 25792493 DOI: 10.1007/s00198-015-3103-4] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2015] [Accepted: 03/06/2015] [Indexed: 11/29/2022]
Abstract
UNLABELLED We evaluated the secondary fracture prevention in 1445 patients with distal radius fracture by trauma surgeons. The rate of patients with distal radius fracture who underwent bone mineral density (BMD) examination was low, suggesting that appropriate treatment for osteoporosis by trauma surgeons is not performed at present. INTRODUCTION To clarify the status of osteoporosis interventions after distal radial fractures by trauma surgeons who play the main role in treatment for these fractures, we performed a survey involving multiple institutions in Japan. METHODS We asked 155 board members of the Japanese Society for Fracture Repair for their cooperation and performed a survey in 48 institutions with which members who gave cooperation were affiliated. The subjects consisted of consecutive patients with distal radial fractures occurring between January and December 2012. The presence or absence of a diagnosis of osteoporosis and bone mineral density examination after fracture was investigated. RESULTS A total of 1445 patients with distal radial fractures were evaluated in this study. BMD examination for diagnosis and treatment for osteoporosis after fracture was performed respectively in 126 (8.7 %) and 193 (13.4 %) of 1445 patients. Treatment for osteoporosis was performed in 93 (73.8 %) of 126 patients who underwent BMD examination after fracture and 100 (8.2 %) of 1219 who did not undergo BMD examination. Of the 126 patients who underwent BMD examination after fracture, 89 showed a BMD <80 % of the young adult mean as a criterion for the initiation of drug treatment for osteoporosis in Japan and 77 (86.5 %) of the 89 patients were treated with drugs. CONCLUSIONS The rate of patients with distal radial fractures who underwent BMD examination was low, suggesting that appropriate treatment for osteoporosis by trauma surgeons is not performed at present.
Collapse
Affiliation(s)
- T Baba
- Department of Orthopaedic Surgery, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan,
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Matsumoto Y, Lee JH, Morimoto T, Nakanishi R, Nishimura S, Baba T, Oka H, Kakei S, Okada Y, Ando H, Kawamata T. Quantitative evaluation of movement disorder of wrist joint in patients with cerebral, thalamic and cerebellar stroke. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.1820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
29
|
Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 2015; 112:1501-9. [PMID: 25867264 PMCID: PMC4453666 DOI: 10.1038/bjc.2015.101] [Citation(s) in RCA: 500] [Impact Index Per Article: 55.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Revised: 02/19/2015] [Accepted: 02/19/2015] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND PD-L1 (programmed cell death 1 ligand 1) on tumour cells suppresses host immunity through binding to its receptor PD-1 on lymphocytes, and promotes peritoneal dissemination in mouse models of ovarian cancer. However, how PD-L1 expression is regulated in ovarian cancer microenvironment remains unclear. METHODS The number of CD8-positive lymphocytes and PD-L1 expression in tumour cells was assessed in ovarian cancer clinical samples. PD-L1 expression and tumour progression in mouse models under conditions of altering IFN-γ signals was assessed. RESULTS The number of CD8-positive cells in cancer stroma was very high in peritoneally disseminated tumours, and was strongly correlated to PD-L1 expression on the tumour cells (P<0.001). In mouse models, depleting IFNGR1 (interferon-γ receptor 1) resulted in lower level of PD-L1 expression in tumour cells, increased the number of tumour-infiltrating CD8-positive lymphocytes, inhibition of peritoneal disseminated tumour growth and longer survival (P=0.02). The injection of IFN-γ into subcutaneous tumours induced PD-L1 expression and promoted tumour growth, and PD-L1 depletion completely abrogated tumour growth caused by IFN-γ injection (P=0.01). CONCLUSIONS Interferon-γ secreted by CD8-positive lymphocytes upregulates PD-L1 on ovarian cancer cells and promotes tumour growth. The lymphocyte infiltration and the IFN-γ status may be the key to effective anti-PD-1 or anti-PD-L1 therapy in ovarian cancer.
Collapse
Affiliation(s)
- K Abiko
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - N Matsumura
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - J Hamanishi
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - N Horikawa
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - R Murakami
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - K Yamaguchi
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Y Yoshioka
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - T Baba
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - I Konishi
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - M Mandai
- Department of Obstetrics and Gynecology, Faculty of Medicine, Kinki University, 377-2 Onohigashi, Osakasayama, Osaka 589-0014, Japan
| |
Collapse
|
30
|
|
31
|
Hiramatsu K, Katayama Y, Matsuo M, Sasaki T, Morimoto Y, Sekiguchi A, Baba T. Multi-drug-resistant Staphylococcus aureus and future chemotherapy. J Infect Chemother 2014; 20:593-601. [PMID: 25172776 DOI: 10.1016/j.jiac.2014.08.001] [Citation(s) in RCA: 129] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2014] [Revised: 07/31/2014] [Accepted: 08/01/2014] [Indexed: 11/17/2022]
Abstract
Staphylococcus (S.) aureus silently stays as our natural flora, and yet sometimes threatens our life as a tenacious pathogen. In addition to its ability to outwit our immune system, its multi-drug resistance phenotype makes it one of the most intractable pathogenic bacteria in the history of antibiotic chemotherapy. It conquered practically all the antibiotics that have been developed since 1940s. In 1961, the first MRSA was found among S. aureus clinical isolates. Then MRSA prevailed throughout the world as a multi-resistant hospital pathogen. In 1997, MRSA strain Mu50 with reduced susceptibility to vancomycin was isolated. Vancomycin-intermediate S. aureus (VISA), so named according to the CLSI criteria, was the product of adaptive mutation of S. aureus against vancomycin that had long been the last resort to MRSA infection. Here, we describe the genetic basis for the remarkable ability of S. aureus to acquire multi-antibiotic resistance, and propose a novel paradigm for future chemotherapy against the multi-resistant pathogens.
Collapse
Affiliation(s)
- K Hiramatsu
- Research Center for Infection Control Science, Juntendo University, 2-1-1 Hongo, Bunkyo-Ku, Tokyo, Japan.
| | - Y Katayama
- Research Center for Infection Control Science, Juntendo University, 2-1-1 Hongo, Bunkyo-Ku, Tokyo, Japan
| | - M Matsuo
- Research Center for Infection Control Science, Juntendo University, 2-1-1 Hongo, Bunkyo-Ku, Tokyo, Japan
| | - T Sasaki
- Research Center for Infection Control Science, Juntendo University, 2-1-1 Hongo, Bunkyo-Ku, Tokyo, Japan
| | - Y Morimoto
- Research Center for Infection Control Science, Juntendo University, 2-1-1 Hongo, Bunkyo-Ku, Tokyo, Japan
| | - A Sekiguchi
- Research Center for Infection Control Science, Juntendo University, 2-1-1 Hongo, Bunkyo-Ku, Tokyo, Japan
| | - T Baba
- Research Center for Infection Control Science, Juntendo University, 2-1-1 Hongo, Bunkyo-Ku, Tokyo, Japan
| |
Collapse
|
32
|
Abstract
Dynamic wavelength conversion (DWC) is obtained by controlling copropagating slow-light signal and control pulse trajectories. Our method is based on the understanding that conventional resonator-based DWC can be generalized, and is linked to cross-phase modulation. Dispersion-engineered Si photonic crystal waveguides produce such slow-light pulses. Free carriers generated by two-photon absorption of the control pulse dynamically shift the signal wavelength. Matching the group velocities of the two pulses enhances the shift, elongating the interaction length. We demonstrate an extremely large wavelength shift in DWC (4.9 nm blueshift) for the signal wavelength. Although DWC is similar to the Doppler effect, we highlight their essential differences.
Collapse
Affiliation(s)
- K Kondo
- Department of Electrical and Computer Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogayaku, Yokohama 240-8501, Japan
| | - T Baba
- Department of Electrical and Computer Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogayaku, Yokohama 240-8501, Japan
| |
Collapse
|
33
|
Baba T, Kharma B, Matsumura N, Yamaguchi K, Hamanishi J, Abiko K, Konishi I. STAT1 pathway promotes progression of serous papillary endometrial cancer. Gynecol Oncol 2014. [DOI: 10.1016/j.ygyno.2014.03.484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
34
|
Yamaguchi K, Amano Y, Matsumura N, Mandai M, Abiko K, Hamanishi J, Yoshioka Y, Baba T, Konishi I. HNF1B contributes to resistance to oxidative stress through modification of metabolism in ovarian clear cell carcinoma. Gynecol Oncol 2014. [DOI: 10.1016/j.ygyno.2014.03.232] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
35
|
Masuda Y, Baba T, Suzuki M. Application of supernodal sparse factorization and inversion to the estimation of (co)variance components by residual maximum likelihood. J Anim Breed Genet 2013; 131:227-36. [PMID: 24906028 DOI: 10.1111/jbg.12058] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2012] [Accepted: 09/12/2013] [Indexed: 11/29/2022]
Abstract
We demonstrated that supernodal techniques were more efficient than traditional methods for factorization and inversion of a coefficient matrix of mixed model equations (MME), which are often required in residual maximum likelihood (REML). Supernodal left-looking and inverse multifrontal algorithms were employed for sparse factorization and inversion, respectively. The approximate minimum degree or multilevel nested dissection was used for ordering. A new computer package, Yet Another MME Solver (YAMS), was developed and compared with FSPAK with respect to computing time and size of temporary memory for 13 test matrices. The matrices were produced by fitting animal models to dairy data and by using simulations from sire, sire-maternal grand sire, maternal and dominance models for phenotypic data and animal model for genomic data. The order of matrices ranged from 32,840 to 1,048,872. The YAMS software factorized and inverted the matrices up to 13 and 10 times faster than FSPAK, respectively, when an appropriate ordering strategy was applied. The YAMS package required at most 282 MB and 512 MB of temporary memory for factorization and inversion, respectively. Processing time per iteration in average information REML was reduced, using YAMS. The YAMS package is freely available on request by contacting the corresponding author.
Collapse
Affiliation(s)
- Y Masuda
- Department of Life Science and Agriculture, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Japan
| | | | | |
Collapse
|
36
|
Abou-Taleb H, Yamaguchi K, Mandai M, Yamanoi K, Amano Y, Matsumura N, Baba T, Yoshioka Y, Hamanishi J, Konishi I. Role of ARID1A for the clinicopathologic characteristics of clear cell carcinoma (CCC) of the ovary. Gynecol Oncol 2013. [DOI: 10.1016/j.ygyno.2013.04.361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
37
|
Kondo K, Shinkawa M, Hamachi Y, Saito Y, Arita Y, Baba T. Ultrafast slow-light tuning beyond the carrier lifetime using photonic crystal waveguides. Phys Rev Lett 2013; 110:053902. [PMID: 23414021 DOI: 10.1103/physrevlett.110.053902] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/20/2012] [Indexed: 06/01/2023]
Abstract
We demonstrate ultrafast delay tuning of a slow-light pulse with a response time <10 ps. This is achieved using two types of slow light: dispersion-compensated slow light for the signal pulse, and low-dispersion slow light to enhance nonlinear effects of the control pulse. These two types of slow light are generated simultaneously in Si lattice-shifted photonic crystal waveguides, arising from flat and straight photonic bands, respectively. The control pulse blueshifts the signal pulse spectrum, through dynamic tuning caused by the plasma effect of two-photon-absorption-induced carriers. This changes the delay by up to 10 ps only when the two pulses overlap within the waveguide and enables ultrafast tuning that is not limited by the carrier lifetime. Using this, we succeeded in tuning the delay of one target pulse within a pulse train with 12 ps intervals.
Collapse
Affiliation(s)
- K Kondo
- Department of Electrical and Computer Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogayaku, Yokohama 240-8501, Japan
| | | | | | | | | | | |
Collapse
|
38
|
|
39
|
Ikeda K, Baba T, Noguchi H, Nagasawa K, Endo T, Kiya T, Saito T. Excessive androgen exposure in female-to-male transsexual persons of reproductive age induces hyperplasia of the ovarian cortex and stroma but not polycystic ovary morphology. Hum Reprod 2012. [DOI: 10.1093/humrep/des385] [Citation(s) in RCA: 101] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Kato T, Baba T, Yamaguchi O, Yoshida M, Oda T, Takasa A, Enomoto T, Shinohara T, Hagiwara E, Ogura T. A Prospective, Feasibility Study of S-1 and Carboplatin for Patients with Advanced Non Small Cell Lung Cancer (NSCLC) Concomitant with Pulmonary Fibrosis (PF). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33795-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
41
|
Hamano R, Baba T, Kawano M, Yamagishi M, Mukaida N. P179 Antigen-specific regulation of immune reaction by systemically expanded Tregs against blood-borne antigen. Cytokine 2012. [DOI: 10.1016/j.cyto.2012.06.281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
42
|
Mukaida N, Baba T, Sasaki S. P163 Crucial involvement of the CCL3-CCR5 axis in fibrosis accompanied with mouse chronic colitis-associated carcinogenesis. Cytokine 2012. [DOI: 10.1016/j.cyto.2012.06.264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
43
|
Baba T, Kharma B, Mandai M, Yoshioka Y, Hamanishi J, Matsumura N, Yamaguchi K, Murphy S, Konishi I. Utilization of genomic signatures to identify Fludarabine and Temsirolimus as candidate drugs with high efficacy to chemo-refractory endometrial cancers. Gynecol Oncol 2012. [DOI: 10.1016/j.ygyno.2011.12.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
44
|
Baba T, Uramoto H, Kuwata T, Oka S, Shigematsu Y, Nagata Y, Shimokawa H, Takenoyama M, Hanagiri T, Tanaka F. A Study of Surgically Resected Peripheral Non-Small Cell Lung Cancer with a Tumor Diameter of 1.0 CM or Less. Scand J Surg 2011; 100:153-8. [DOI: 10.1177/145749691110000303] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background and Aims: The widespread use of high resolution computed tomography has increased the number of small peripheral lung cancers. This study reviewed the clinicopathological features of the patients with non-small cell lung cancer (NSCLC) with a tumor diameter of 1 cm or less, in order to explore the adequate management of such small sized lung cancers. Material and Methods: This study was a retrospective analysis of consecutive 58 patients (5.3% out of 1095 patients) who underwent a complete resection for a peripheral NSCLC with a diameter of 1.0 cm or less. The clinical features and outcomes were compared with 203 patients with NSCLC with a diameter between 1.1 and 2.0 cm. Results: The mean age was 64.5 years and there were 26 males and 32 females. Clinical stage was IA in 57 (98%) and IIIA in 1. Lobectomy was performed in 39 patients, segmentectomy in nine, and nonanatomic wedge resection in ten. Two patients, who underwent systemic lymph node dissection, had mediastinal lymph node metastasis and were diagnosed as pathological stage IIIA; however they did not relapse after surgery. One patient with pathological stage IA papillary adenocarcinoma died due to brain metastases. The five-year overall survival rate and disease free survival rate was 95.0% and 95.3%, respectively. Patients with NSCLC of 1.0 cm or less showed significantly better survival than those with tumors measuring 1.1–2.0 cm in size (p = 0.048). Discussion: The indications for avoiding systemic lymph node dissection for operable NSCLC should not be based on the size of the tumor. A small-sized lung cancer might be surgically treated before the tumor enlarges to more than 1.0 cm in size.
Collapse
Affiliation(s)
- T. Baba
- Department of Surgery II, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - H. Uramoto
- Department of Surgery II, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - T. Kuwata
- Department of Surgery II, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - S. Oka
- Department of Surgery II, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Y. Shigematsu
- Department of Surgery II, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Y. Nagata
- Department of Surgery II, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - H. Shimokawa
- Department of Surgery II, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - M. Takenoyama
- Department of Surgery II, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - T. Hanagiri
- Department of Surgery II, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - F. Tanaka
- Department of Surgery II, University of Occupational and Environmental Health, Kitakyushu, Japan
| |
Collapse
|
45
|
Yamaguchi K, Baba T, Konishi I, Matsumura N, Murphy S, Huang Z, Berchuck A. Genes functionally regulated by methylation in ovarian cancer are involved in cell proliferation, development and morphogenesis. Gynecol Oncol 2011. [DOI: 10.1016/j.ygyno.2010.12.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
46
|
Baba T, Matsuyama T, Sawada T, Takahama T, Wakisaka K, Tsuda S. High-Quality Polycrystalline Silicon Thin Film Prepared by a Solid Phase Crystallization Method. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-358-895] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTWe succeeded, for the first time, in depositing a silicon film which features 1000Å-wide single-crystalline grains embedded in a matrix of amorphous tissue. The deposition was done by plasma-enhanced CVD from silane diluted with hydrogen at a considerably high temperature (550°C). 5pm-thick undoped amorphous silicon film was deposited on the above film and was crystallized by a solid phase crystallization method. The polycrystalline silicon film which was obtained has a columnar structure and shows an extremely high electron mobility of 808 cm2/Vs.
Collapse
|
47
|
Abstract
AbstractGaN films with good crystalline quality are grown on sapphire by atmospheric pressure vapor phase epitaxy using gallium tri-chloride (GaCl3) and ammonia (NH3). Epitaxial growth is carried out over temperature and V/III-ratio ranges of 800–1000°C and 100–1000, respectively. Typical growth rate obtained is in the range of 5–20 μm/hr. The films grown below 925°C typically show three dimensional (island) growth, while above that temperature, continuous films are obtained. Films grown at 975°C with a V/III ratio > 300 exhibit a smooth surface. XRD analysis shows that the films are single crystal with hexagonal polytype. Strong band-edge photoluminescence is observed with a FWHM of 60 meV at room temperature and 25 meV at 77K. The results indicate that this simple growth technique is effective for growing high quality bulk GaN, which can be used as a substrate for subsequent epitaxy. In order to further improve the surface morphology, a preliminary experiment on GaN growth on a thin GaN buffer layer prepared by gas source MBE is also presented.
Collapse
|
48
|
Oka S, Hanagiri T, Takenaka M, Baba T, Yasuda M, Ono K, Uramoto H, Takenoyama M, Yasumoto K. [Surgical treatment for patients with descending necrotizing mediastinitis]. Kyobu Geka 2010; 63:1022-1025. [PMID: 21066840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Descending necrotizing mediastinitis (DNM) originating from deep cervical infection is a rare and serious clinical condition with a high mortality rate. Clinical feature of 5 patients undergone surgical drainage for DNM, between 2006 and 2009 were assessed. There were 3 male and 2 female patients whose age ranged from 57 to 83 years old (mean 69.8). All 5 patients had no underlying disease except for 1 patient with severe dental caries. The primary infections of these patients were tonsillitis and pharyngitis. The mean duration from onset of symptom to the referral to our hospital was 14 days (ranged 2 to approximately 41). Two patients underwent cervical drainage for upper mediastinum, and 3 patients were required mediastinal drainage by thoracotomy. There was no post-operative death. Early and aggressive surgical drainage of the neck and mediastinum by a multidisciplinary team of surgeons is very important in the treatment of DNM.
Collapse
Affiliation(s)
- S Oka
- Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Yamaguchi Y, Touchi A, Baba T, Matsubara T. Species differences in β-oxidative metabolism of a thromboxane A2-receptor antagonist [(+)-S-145] in rat, dog and monkey. Xenobiotica 2010. [DOI: 10.1080/0049825011004350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
50
|
Barcelona PF, Luna JD, Chiabrando GA, Juarez CP, Bhutto IA, Baba T, McLeod DS, Sánchez MC, Lutty GA. Immunohistochemical localization of low density lipoprotein receptor-related protein 1 and alpha(2)-Macroglobulin in retinal and choroidal tissue of proliferative retinopathies. Exp Eye Res 2010; 91:264-72. [PMID: 20561980 DOI: 10.1016/j.exer.2010.05.017] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2010] [Revised: 04/29/2010] [Accepted: 05/24/2010] [Indexed: 01/22/2023]
Abstract
The immunolocalization of the low density lipoprotein receptor-related protein 1 (LRP1) and its ligand alpha 2-Macroglobulin (alpha(2)M) was examined in tissues from human donor eyes of normal, diabetic and sickle cell disease subjects. Streptavidin alkaline phosphatase immunohistochemistry was performed with a mouse anti-human LRP1 and rabbit anti-human alpha(2)M antibodies. Retinal and choroidal blood vessels were labeled with mouse anti-human CD34 antibody in adjacent tissue sections. Mean scores for immunostaining from the pathological and control eyes were statistically compared. LRP1 immunoreactivity was very weak to negative in the neural retina of normal subjects except in scattered astrocytes. LRP1 expression in diabetic eyes was detected in the internal limiting membrane (ILM), astrocytes, inner photoreceptor matrix, choriocapillaris and choroidal stroma. The ligand alpha(2)M, however, was limited mainly to blood vessel walls, some areas of the inner nuclear layer (INL), photoreceptors, RPE-Bruch's membrane-choriocapillaris complex, intercapillary septa, and choroidal stroma. In sickle cell eyes, avascular and vascular retina as well as choroidal neovascularization (CNV) were analyzed. In avascular areas, LRP1 immunoreactivity was in innermost retina (presumably ILM, astrocytes, and Muller cells) and INL as well as RPE-Bruch's membrane-choriocapillaris complex and choroidal stroma. alpha(2)M was very weak in avascular peripheral retina compared to vascularized areas and limited to stroma in choroid. In contrast, in areas with CNV, LRP1 immunoreactivity was significantly decreased in overlying retina and in RPE-Bruch's membrane and choroidal stroma compared to the controls, while alpha(2)M was elevated in RPE-Bruch's membrane near CNV compared to normal areas in sickle cell choroid. The mean scores revealed that LRP1 and alpha(2)M in neural retina were significantly elevated in astrocytes and ILM in diabetic eyes (p < or = 0.05), whereas in sickle cell eyes scores were elevated in ILM and INL (p < or = 0.05). In addition, alpha(2)M immunoreactivity was in photoreceptors in both ischemic retinopathies. In choroid, the patterns of LRP1 and alpha(2)M expression were different and not coincident. This is the first demonstration of the presence of LRP1 and alpha(2)M in human proliferative retinopathies. Elevated LRP1 expression in sickle cell neural retina and diabetic inner retina and choroid suggests that LRP1 plays an important role in ischemic neovascular diseases.
Collapse
Affiliation(s)
- P F Barcelona
- Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI)-CONICET, Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre y Medina Allende, Ciudad Universitaria (5000) Córdoba, Argentina
| | | | | | | | | | | | | | | | | |
Collapse
|